SUMMARY -Postoperative atrial fi brillation is a common complication after lung resection. It is burdened by increased mortality and morbidity, prolonged hospitalization, and higher resource utilization in thoracic surgery patients. Th erefore, some kind of pharmacological prophylaxis is recommended. In our patients, diltiazem, a calcium antagonist, is administered. We collected data on all 608 patients having undergone lung resection (no less than lobectomy) between November 2012 and May 2015. Th is period included patients having received diltiazem during their postoperative stay in our Intensive Care Unit and surgical ward, and those that did not receive it. Patients having had atrial fi brillation before the surgery and patients with cardiac pacemaker were excluded from the trial. Other patients were divided into three groups: patients with some kind of antiarrhythmic therapy before and continued after the surgery; patients with diltiazem prophylaxis; and patients without any antiarrhythmic prophylaxis. Th e data collected were statistically analyzed. We found no statistically signifi cant diff erence in the incidence of postoperative atrial fi brillation among the groups (p<0.05).
Introduction
According to the literature, postoperative atrial fibrillation (POAF) (or equivalent supraventricular arrhythmia) is a common complication after pulmonary and esophageal surgery, with the incidence between 12% and 44% 1, 2 . Some risk factors have been identifi ed, correlation with perioperative mortality and morbidity has been demonstrated, and prophylactic and therapeutic guidelines have been developed 1, 2 . POAF is associated with hemodynamic instability, heart failure, thromboembolic events, higher resource utilization and, possibly, increased mortality 1 . Th e precise mechanism of POAF development is not well understood 1 . Th e risk factors include history of smoking, obesity, advancing age, atrial dilatation, myocardial ischemia, volume overload, history of heart failure, increased adrenergic and vagal tone, and surgical procedures associated with local or systemic infl ammation 1, 2 . Th e extent of pulmonary resection is of importance as a risk factor, with the highest rates of incidence noted after pneumonectomies, extrapleural pneumonectomies and lung transplantations 2 . Lobectomies and pneumonectomies are recognized as high risk procedures with POAF incidence above 15% 1 . Among drugs recommended for the prophylaxis of POAF and equivalent postoperative arrhythmias is diltiazem, a calcium antagonist 2, 3 . It has few side eff ects and, with respect to known contraindications, it is well tolerated, especially in patients with chronic obstructive pulmonary disease (COPD) 2 .
Patients and Methods
Th is observational study was performed at Jordanovac Department of Th oracic Surgery, Zagreb University Hospital Centre, Zagreb, Croatia. Data from med-ical records of all patients having undergone pulmonary resection procedures with a high risk of POAF 1 (lobectomies, bilobectomies and pneumonectomies) between November 2012 and May 2015 were included in the study. It was the time of introducing diltiazem for atrial fi brillation (AF) prophylaxis in our patients, thus including patient data before and during the introduction of diltiazem prophylaxis. Th e following data were collected: patient age, sex, the American Society of Anesthesiologists Physical Status (ASA status), comorbidity (coronary disease, arterial hypertension, other cardiac diseases and arrhythmias, preoperative chemotherapy, preoperative irradiation, hypo-/ hyperthyroidism, diabetes mellitus, renal insuffi ciency, alcoholic cirrhosis, concomitant malignancy), relevant preoperative drug therapy, lung resection type (extent, intrapericardial, extrapleural), use/no use of thoracic epidural analgesia (TEA), use/no use of POAF prophylaxis (and if, what kind), presence/absence of postoperative fi brillation and equivalent arrhythmia, and the highest ventricular response recorded during POAF. Th e choice of risk factors and collected data was determined by the data available from medical records. All patients had spent at least one night, most of them two or more nights, in the Intensive Care Unit (ICU) before they were admitted to thoracic surgery ward. Patients were divided into three groups: group A included patients with no POAF prophylaxis; group B included patients with diltiazem prophylaxis; and group C included patients with preoperative antiarrhythmic therapy (mostly beta-blockers, a few propafenone or amiodarone) that was continued postoperatively. Diltiazem was included in therapy, if there were no contraindications, on the day of surgery or the fi rst postoperative day (according to clinical circumstances) and continued after transfer from ICU to surgical ward. A patient was included in group B if the 24-hour diltiazem dose was at least 60 mg (usually it was between 60 mg and 240 mg per os divided in 2-4 doses). All patients were treated equally according to the ICU and surgical ward perioperative treatment protocol. All patients gave their informed consent for participation in the study. Statistical analysis and data analysis were done by the licensed STATISTI-CA 6. 
Results
Th ere were 608 patients undergoing lung resection greater or equal to lobectomy during the period of 31 months. As 15 patients with chronic AF and four patients with some kind of pacemaker were excluded, there remained 589 patients with lung resection for further analysis (Table 1) . Seventy-seven of these 589 patients developed POAF (13.1%) ( Table 2 ). Th ere were 82 pneumonectomies with 19 (23.17%) cases of POAF. According to their AF prophylaxis, these 589 patients were divided into 3 groups: group A, 236 patients without prophylaxis; group B, 221 patients with diltiazem prophylaxis; and group C, 132 patients with continued preoperative antiarrhythmic therapy (Table 3) . POAF was recorded in 34 (14.41%) group A patients, 27 (12.22%) group B patients and 16 (12.12%) group C patients. Th e highest ventricular response in AF was recorded in each patient, with median 160 (range 91-230) in group A, 150 (range Fig.  1 ). Analysis of variance (ANOVA) yielded no statistically signifi cant diff erence among patients with diff erent AF prophylaxis with respect to the highest ventricular frequency. Patients without prophylactic antiarrhythmic drugs had higher ventricular frequency during AF but this diff erence was not statistically signifi cant (p>0.05) ( Table 6 , Fig. 2 ). Analysis of correlation of particular risk factors with POAF yielded statistically signifi cant correlation (p<0,05) for age (Tables 7, 8 and 9), sex (Tables 10, 11 and 12), pneumonectomy versus other resections (Tables 13, 14, 15 and  16) , generalized atherosclerotic disease (in our study, it was defi ned as comorbidity including history of myocardial infarction or cerebrovascular insult, diagnosis of coronary disease and peripheral vascular disease) (Tables 17, 18 and 19), and ASA status (Tables 20, 21 and 22). Considering other states and comorbidities, (Tables 23, 24 and 25), arterial hypertension (Tables 26, 27 and 28) and prior chemotherapy (Tables 29, 30 and 31), or the entities were too rare in our patients to be included in the analysis, e.g., diabetes mellitus, renal insuffi ciency and Teolin therapy.
Discussion
Th e search for the ideal antiarrhythmic for POAF prophylaxis is far from fi nished. Avoidance of β blockade withdrawal in patients on chronic therapy with these medications is the simple and most eff ective preventive measure 1, 2, 4 . As with AF therapy, there is no ideal drug or method for POAF prevention in other patients. Magnesium supplementation is usually rec- . Diltiazem is a nondihydropyridine calcium channel antagonist (class IV Vaughan Williams agent) 6 . As AF prophylaxis, we administer it in oral form. In our study, we found no statistically signifi cant diff erence between patient groups with and without diltiazem prophylaxis, suggesting that in our patients, POAF occurred as a complication of lung resection comparably often with and without diltiazem prophylaxis. So, we could not confi rm the report by Amar et al. on diltiazem therapy and its signifi cant POAF rate reduction 3 . Our speculation that patients with diltiazem prophylaxis generally have somewhat slower ventricular response during POAF (median 150; without any prophylaxis, median 160), which could have some protective properties per se, was not confi rmed by statistical analysis. Maybe the most problematic part of the study was the uneven dosage of diltiazem postoperatively, especially on day 0; also, underdosing was probably quite common due to hemodynamic instability of patients at that time. However, Hiran et al. 2 in their guidelines suggest that diltiazem prophylaxis per os be initiated in recovery room at a dose of 30-60 mg every 6 hours, depending on the patient related factors and with "hold parameters", and we did so accordingly. Th ere is also the issue of the oral route of taking the drug and its gastrointestinal resorption in the early postoperative course. In our study, the incidence of POAF was 13.1%, which is consistent 2 , where it is reported to be 12%-44%. If we exclude pneumonectomies, then our POAF incidence was 11.4%. As most of our patients were transferred from the ICU on postoperative day 2, we can speculate that there were much more unnoticed and asymptomatic POAF episodes on surgical ward. We confi rmed literature reports on patient age, sex, pneumonectomy (especially intrapericardial and extrapleural extensions) and generalized atherosclerotic disease (i.e. coronary disease) as risk factors 1,2 (statistically signifi cant results). Some other risk factors could not be confi rmed due to the relatively low number of aff ected patients in our sample (hyperthyroidism, cardiac diseases other than coronary disease, arrhythmias, diabetes mellitus, etc.) 1, 2 . We believe that there were more patients with these risk factors, but it was not recorded in their medical documentation. It should be noted that we found a statistically signifi cant correlation between ASA status and POAF, but not between epidural analgesia/anesthesia and POAF. ASA status, as stated in the literature, correlates with perioperative mortality "even better than other classifi cations of mortality and morbidity" 7, 8 . TEA is considered to exert some protective eff ect against POAF 9 . Arterial hypertension was not confi rmed as a risk factor for POAF, in contrast to the 2014 American Heart Association Atrial Fibrillation Guidelines and relevant literature 1, 2, 4 . Preoperative chemotherapy, indicated as a risk factor for postoperative cardiovascular events 10 , does not seem to increase the risk of POAF. To establish more defi nitive conclusions, additional study in a bigger sample and including more and better defi ned risk factors is needed.
